UBS maintained an “outperform” rating on the biotechnology company. From This entry was posted on Wednesday, November 30th, 2005 at 5:14 pm and is filed under General updates. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.